source
- Biomarker-Driven Treatment Decisions and Managing Progression After Frontline ImmunotherapyUpfront biomarker testing reshapes endometrial cancer care, guiding targeted and immune therapy—and exposing gaps in second-line options.onclive · 2mo ago↗ source
- Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast CancerKelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.onclive · 2mo ago↗ source
- Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie BondDr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.